Zydus Cadila gets USFDA nod for low Blood Pressure drug

The newly approved medication will be manufactured at the group's formulation manufacturing facility at SEZ, Ahmedabad.

Picture: Pixabay

Last Updated on February 19, 2021 by The Health Master

Zydus Cadila on Friday said it has received final approval from the US health regulator to market Droxidopa capsules, used to treat low blood pressure.

Zydus Cadila has received final approval from the United States Food and Drug Administration (USFDA) to market Droxidopa capsules in the strength of 100 mg, 200 mg, and 300 mg, Cadila Healthcare said in a regulatory filing.

Zydus Cadila is part of the Cadila Healthcare group.

Droxidopa works by constricting (narrowing) the blood vessels and increasing blood pressure. It is used to treat low blood pressure that causes severe dizziness or a lightheaded feeling.

The company further said that Droxidopa is indicated for use in people with conditions of the nervous system that can cause low blood pressure (such as Parkinson’s disease, multiple system atrophy, autonomic failure, and others).

The newly approved medication will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad.

The group now has 312 approvals and has so far filed over 400 abbreviated new drug applications since the commencement of the filing process in financial year 2003-04.

Shares of Cadila Healthcare were trading 1.51 per cent lower at Rs 460.45 apiece on BSE.

Also read:

Lupin launches Posaconazole Delayed-Release Tablets

Glenmark launches Kidney drug at 96% lower price

Lupin, Aurobindo units recall medicines in US market

Alembic gets USFDA final nod for Treprostinil injection

The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.

Go to main website, click here

Follow and connect with us on Facebook and Linkedin

Subscribe for daily free updates, click here

For daily free updates on WhatsApp, click here

Subscribe here for daily updates